Amylyx Pharma Q4 2023 GAAP EPS $0.07 Misses $0.23 Estimate, Sales $108.45M Beat $106.96M Estimate
Portfolio Pulse from Benzinga Newsdesk
Amylyx Pharma (NASDAQ:AMLX) reported Q4 2023 earnings of $0.07 per share, missing the $0.23 estimate, but sales of $108.45M exceeded the $106.96M forecast, marking a 395.54% increase from last year.
February 22, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Amylyx Pharma reported lower-than-expected Q4 EPS at $0.07, missing estimates by 69.57%, but surpassed sales estimates with $108.45M, a 395.54% YOY increase.
The miss in EPS could negatively impact investor sentiment, while the significant sales beat and year-over-year growth might offset this with a positive outlook. The mixed results present a neutral short-term impact as the market digests both the earnings miss and the sales beat.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100